top of page

Drug Delivery System for Neurological Disorders: Presenting at Colloquia in Bioengineering

Writer: CLUSTREL
CLUSTREL
Nov 11
2 min read

How can innovative nanomaterials and neuroscience come together to improve the treatment of neurological disorders? This was the central question explored by Dr. Audrey Franceschi Biagioni during her presentation, “Drug Delivery Systems for Neurological Disorders,” at the Colloquia in Bioengineering at the University of Modena and Reggio Emilia.


The presentation highlighted how research and innovation in graphene-based nanomaterials and neuroscience can be translated into clinically relevant drug delivery strategies, opening new possibilities for the treatment of neurological disorders.


Understanding the challenge: Delivering drugs to the brain

Developing effective therapies for neurological disorders remains a major challenge. The Central Nervous System (CNS) presents several obstacles to successful drug delivery, including drug instability, limited therapeutic adaptability, delayed therapeutic benefits, and difficulties in delivering drugs to the right place at the right time.


These limitations raise an important question:

How can we improve therapeutic responses while overcoming the limitations of conventional drug delivery systems?


Graphene: A promising material for next-generation drug delivery

In the research paper “Nanomedicine and graphene-based materials: advanced technologies for potential treatments of diseases in the developing nervous system,” authored by Giada Cellot, Audrey Franceschi Biagioni, and Laura Ballerini, graphene-based materials are explored for their potential in biomedical applications.


Thanks to their distinctive properties, graphene-based materials have potential for the development of advanced nanomedicine approaches. In particular, they could serve as nanocarriers for drug delivery systems, helping researchers explore new ways to deliver therapeutic compounds and improve treatment strategies for neurological conditions.


An especially exciting possibility is how CLUSTREL is developing, by combining graphene-based drug delivery platforms with electroencephalography (EEG) sensors.


This approach could enable a more responsive and targeted therapeutic strategy:

  • Monitor: EEG sensors continuously detect and monitor abnormal brain activity.

  • Communicate: Detected irregularities are transmitted to a drug delivery controller.

  • Respond: Once predefined conditions are met, the system activates and releases a prescribed rescue dose.


By connecting brain activity monitoring with controlled drug release, this concept could pave the way for more adaptive, responsive, and personalised therapeutic approaches. Rather than relying solely on conventional treatment schedules.


Inspiring the next generation of bioengineers

Beyond the scientific discussion, the colloquium was also a valuable opportunity to exchange ideas and engage with the next generation of researchers and innovators.

One of the highlights of the event was the students' challenge to design their own novel nanocarrier-based drug delivery systems. Their creativity, enthusiasm, and fresh perspectives demonstrated the exciting potential of interdisciplinary thinking in shaping the future of healthcare.


“A particularly memorable moment was seeing the students take on the challenge of designing their own novel nanocarrier-based drug delivery systems. Their creativity and fresh ideas were inspiring. They are the future innovators shaping healthcare.”, says Audrey Franceschi Biagioni.

Looking ahead

Bringing together nanotechnology, neuroscience, and bioengineering offers exciting opportunities to rethink how neurological disorders may be treated. While translating these innovative concepts into clinical applications requires further research and development, the potential of graphene-based materials and intelligent drug delivery platforms represents an important direction for future investigation!


Stay updated on the CLUSTREL research development and progress by following the project on LinkedIn.

 
 
 

Comments


bottom of page